Samsung Bioepis Continues G

  • Samsung Bioepis’ BRENZYS™ (etanercept) becomes      available in Brazil through Brazil’s public health system, Sistema Único      de Saúde (SUS)

  • Established seven years ago, Samsung Bioepis’      products are now available across five continents: North America, Europe,      Asia, Oceania, and Latin America. 

INCHEON, KOREA -- (BUSINESS WIRE) --

Samsung Bioepis Co., Ltd. today announced its expansion into the Brazilian biopharmaceutical market. The first product available in the country is BRENZYS™ (etanercept), a biosimilar referencing ENBREL®.i BRENZYS™ was approved by Agência Nacional de Vigilância Sanitária (ANVISA), the country’s health regulatory agency, in December 2017 for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and non-radiographic axial spondyloarthritis.

Samsung Bioepis is continuing its business expansion in multiple markets across the world, including mainland China, where the company entered into partnerships with 3SBio and C-Bridge Capital to develop and commercialize multiple biosimilar candidates from Samsung Bioepis.

BRENZYS™ is being supplied to Sistema Único de Saúde (SUS), the country’s public health system, through a Productive Development Partnership (PDP) between Samsung Bioepis and local partners, Bionovis and Bio-Manguinhos/Fiocruz.

Under the PDP, Samsung Bioepis will supply biosimilar products or product intermediaries to the local partners for sale to SUS for a period of 10 years. During this period, Samsung Bioepis will provide technology transfer to the local partners, so that manufacturing responsibilities can be gradually transferred to enable local manufacturing in Brazil. The PDP scheme was introduced by the Brazilian government in 2008, in order to expand access to medicines and support the country’s pharmaceutical industry through technology transfer from established companies in return for guaranteed purchases from SUS.

In Brazil, over 75% of patients nationwide rely on SUS for health care coverage.ii While biologics represent approximately 4% of all medicinal products acquired by SUS, they account for approximately 51% of government spending on medicinal products.iii

“We are excited to provide our high-quality biosimilars to patients across Brazil, and look forward to working with our local partners to enhance patient access to high-quality healthcare. Equally important, by sharing our scientific knowledge with our local partners, we hope to do our part in contributing to the long-term development of the Brazilian biopharmaceutical industry,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and health care systems across the world.”

Samsung Bioepis’ products are now available across five continents: North America, Europe, Asia, Oceania, and Latin America. The company currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab), as well as an oncologic biosimilar, ONTRUZANT® (trastuzumab). Over 170,000 patients are currently under treatment with Samsung Bioepis’ biosimilars in Europe. In the United States, the company has one biosimilar – RENFLEXIS® (infliximab-abda) – approved and marketed. ONTRUZANT® (trastuzumab-dttb) received approval from the U.S. Food and Drug Administration (FDA) in January 2019, while ETICOVO™ (etanercept-ykro) and HADLIMA™ (adalimumab-bwwd) received FDA approval in April and July 2019, respectively.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

_____________________________
i ENBREL is a registered trademark of Pfizer
ii Jurberg C, Humphreys G. Brazil's march towards universal coverage. Bull World Health Organ. 2010;88(9):646-7.
iii Debiasi M, et al. Biosimilars in Brazil: The Beginning of an Era of Broader Access. Journal of Cancer Therapy. 2017; 8:814-826.


相关推荐
新闻聚焦
猜你喜欢
热门推荐
  • 省委书记应勇:一起克服困难 加油坚守!

      因疫情防控实行小区(村)封闭式管理后,群众生活物资供应能否跟上,社区配送最后一公里是否打通?省委书记、省新冠肺炎疫......

    02-27    来源:凤凰网综合

    分享
  • 刘新成率民进中央调研组在鄂调研 深化“

      5月7日至8日,全国政协副主席、民进中央常务副主席刘新成率民进中央调研组在武汉市、襄阳市开展深化放管服改革,激发微......

    05-09    来源:湖北日报

    分享
  • 省长王晓东: 坚决打赢特殊场所疫情防控

      2月28日,湖北省委副书记、省长、省新冠肺炎疫情防控指挥部指挥长王晓东在武汉市检查督导监狱、养老院、福利院等特殊场......

    02-28    来源:荆楚资讯网

    分享
  • 武汉市邓州商会助力 河南邓州10万斤爱心

      荆楚资讯网讯(刘忠义 )2月25日,满载着河南省邓州市人民的两大卡车10万斤爱心包菜运送到了武汉,在武昌和江岸志愿者的......

    02-28    来源:荆楚资讯网

    分享
  • 少林寺释延振大师访问天华博物馆

      释延振师傅是少林医宗三十四代传人、国际疼痛康复协会会长、狼牙山佛缘禅寺创建人,广州健康管理有限公司法人,他的到......

    11-11    来源:武汉资讯网络台

    分享
  • 4月8日零时起 武汉市解除离汉离鄂通道管

      荆楚资讯网讯: 2020年3月24日, 湖北省新型冠状病毒感染肺炎疫情防控指挥部发布通知称, 为统筹推进疫情防控和经济社会......

    03-25    来源:荆楚资讯

    分享
  • 中国城市创新竞争力蓝皮书出炉 武汉入前

      创新是引领发展的第一动力,在如火如荼的创新浪潮中,中国各大城市的创新竞争力到底孰强孰弱?今天(21日)上午,社会......

    11-21    来源:北京日报客户端

    分享
  • 黄河水利职业技术学院与水利部人才资源

      4月30日,黄河水利职业技术学院(以下简称该校)与水利部人才资源开发中心(以下简称中心)在北京签订战略合作框架协议。中......

    05-09    来源:湖北新市民报网

    分享
  • 山东临沭县委党史研究中心开展主题党日

      荆楚资讯网讯: 2月27日,山东省临沭县委党史研究中心党支部组织全体党员开展战疫情、勇担当、展风采主题党日活动。 党......

    02-28    来源:荆楚资讯网

    分享
  • 黑龙江云桥米业入驻辽宁受市民青睐

       今(17)日,本着以“征服您的胃,拴住您的腿,勾住您的魂,满足您的嘴”为宗旨的黑龙江泰来云桥米业再开新店,云桥......

    11-17    来源: 时代商网

    分享
返回列表
Ctrl+D 将本页面保存为书签,全面了解最新资讯,方便快捷。